Salta al contenuto principale
Passa alla visualizzazione normale.

FRANCESCO DIELI

Aminobisphosphonates as New Weapons for gammaDelta T Cell-Based Immunotherapy of Cancer

  • Autori: CACCAMO, N; MERAVIGLIA, S; CICERO, G; GULOTTA, G; MOSCHELLA, F; CORDOVA, A; GULOTTA, E; SALERNO, A; DIELI, F
  • Anno di pubblicazione: 2008
  • Tipologia: Articolo in rivista (Articolo in rivista)
  • Parole Chiave: Human gamma delta T cells, tumors, phosphoantigens, bisphosphonates, immunotherapy
  • OA Link: http://hdl.handle.net/10447/37794

Abstract

BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic protocols based on N-aminobisphosphonate administration and several Phase I-II trials are ongoing investigating the activity of zoledronic acid plus IL-2 in solid tumours.